<p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）於週四公佈了其財報。該公司報告本季度每股收益為 0.15 美元，超出市場共識預期的（0.38 美元）0.53 美元，FiscalAI 報道。Apellis Pharmaceuticals 的淨利潤率為 2.23%，股本回報率為 8.20%。該季度的營業收入為 2.683 億美元，而分析師的預期為 2.0358 億美元。</p>
<h2>Apellis Pharmaceuticals 股價下跌 0.3%</h2>
<ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
<p>週四午盤交易中，納斯達克代碼：APLS 的股價下跌 0.11 美元，報 41.01 美元。該股票的交易量為 8,392,532 股，而其平均交易量為 3,822,692 股。Apellis Pharmaceuticals 的 12 個月低點為 16.10 美元，12 個月高點為 41.14 美元。該公司的速動比率為 2.70，流動比率為 3.14，債務股本比率為 0.98。該公司的 50 日簡單移動平均線為 30.34 美元，200 日簡單移動平均線為 25.59 美元。公司的市值為 52.5 億美元，市盈率為 315.49，貝塔值為-0.24。</p>
<h2>對 Apellis Pharmaceuticals 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Invesco Ltd.在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 23.5%。Invesco Ltd.目前擁有 225,976 股該公司的股票，價值 5,677,000 美元，此前在上個季度又購買了 42,960 股。Mackenzie Financial Corp 在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 25.4%。Mackenzie Financial Corp 目前擁有 96,211 股該公司的股票，價值 2,424,000 美元，此前在上個季度又購買了 19,500 股。NewEdge Advisors LLC 在第四季度購買了 Apellis Pharmaceuticals 的新頭寸，價值 366,000 美元。Virtus Investment Advisers LLC 在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 17.4%。Virtus Investment Advisers LLC 目前擁有 27,086 股該公司的股票，價值 680,000 美元，此前在上個季度又購買了 4,013 股。最後，Twinbeech Capital LP 在第四季度將其在 Apellis Pharmaceuticals 的持倉增加了 47.3%。Twinbeech Capital LP 目前擁有 13,152 股該公司的股票，價值 330,000 美元，此前在此期間又購買了 4,225 股。96.29% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>幾位研究分析師最近對該股票進行了評論。美國銀行將 Apellis Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並在 1 月 21 日的報告中設定了 28.00 美元的目標價。摩根大通在 4 月 1 日的報告中重申了 “中性” 評級，並將 Apellis Pharmaceuticals 的目標價設定為 41.00 美元（上調自 37.00 美元）。巴克萊在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元提高至 41.00 美元，並給予該股票 “等權重” 評級。雷蒙德·詹姆斯金融在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “適度買入” 下調至 “持有”。最後，富國銀行在 4 月 17 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “超配” 下調至 “等權重”，並將該股票的目標價從 26.00 美元提高至 41.00 美元。三位股票研究分析師對該股票給予了買入評級，十八位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，Apellis Pharmaceuticals 目前的平均評級為 “持有”，共識目標價為 34.89 美元。</p>
<p><strong>查看我們最新的 APLS 研究報告</strong></p>
<h2>Apellis Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Apellis Pharmaceuticals, Inc.，以納斯達克代碼：APLS 交易，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。該公司的研發工作集中在調節補體蛋白，以解決一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
<p>該公司的主要上市產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，目前正在對其他視網膜疾病進行持續研究。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Apellis Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

APLS

<p>Apellis Pharmaceuticals（納斯達克代碼：APLS）報告的季度每股收益為 0.15 美元，超出預期 0.53 美元。該公司實現收入 2.683 億美元，超過預期的 2.0358 億美元。Apellis 的淨利潤率為 2.23%，股本回報率為 8.20%。儘管財報表現積極，股價仍下跌 0.3%，至 41.01 美元。分析師對該股票的評級不一，普遍目標價為 34.89 美元。該公司專注於開發罕見疾病的治療方案，其主要產品 Syfovre 已獲批准用於地理性萎縮</p>

<p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) announced its earnings results on Thursday. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.38) by $0.53, FiscalAI reports. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $268.30 million during the quarter, compared to analysts' expectations of $203.58 million.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）於週四公佈了其財報。該公司報告本季度每股收益為 0.15 美元，超出市場共識預期的（0.38 美元）0.53 美元，FiscalAI 報道。Apellis Pharmaceuticals 的淨利潤率為 2.23%，股本回報率為 8.20%。該季度的營業收入為 2.683 億美元，而分析師的預期為 2.0358 億美元。</p>
</div><h2>Apellis Pharmaceuticals Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股價下跌 0.3%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
</div><p>Shares of NASDAQ:APLS traded down $0.11 during midday trading on Thursday, hitting $41.01. The stock had a trading volume of 8,392,532 shares, compared to its average volume of 3,822,692. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $41.14. The company has a quick ratio of 2.70, a current ratio of 3.14 and a debt-to-equity ratio of 0.98. The business's 50-day simple moving average is $30.34 and its 200-day simple moving average is $25.59. The company has a market cap of $5.25 billion, a P/E ratio of 315.49 and a beta of -0.24.</p>
<div class="lb-trans"><p>週四午盤交易中，納斯達克代碼：APLS 的股價下跌 0.11 美元，報 41.01 美元。該股票的交易量為 8,392,532 股，而其平均交易量為 3,822,692 股。Apellis Pharmaceuticals 的 12 個月低點為 16.10 美元，12 個月高點為 41.14 美元。該公司的速動比率為 2.70，流動比率為 3.14，債務股本比率為 0.98。該公司的 50 日簡單移動平均線為 30.34 美元，200 日簡單移動平均線為 25.59 美元。公司的市值為 52.5 億美元，市盈率為 315.49，貝塔值為-0.24。</p>
</div><h2>Hedge Funds Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Apellis Pharmaceuticals 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. grew its stake in shares of Apellis Pharmaceuticals by 23.5% in the fourth quarter. Invesco Ltd. now owns 225,976 shares of the company's stock valued at $5,677,000 after buying an additional 42,960 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Apellis Pharmaceuticals by 25.4% in the fourth quarter. Mackenzie Financial Corp now owns 96,211 shares of the company's stock valued at $2,424,000 after buying an additional 19,500 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $366,000. Virtus Investment Advisers LLC grew its stake in shares of Apellis Pharmaceuticals by 17.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 27,086 shares of the company's stock valued at $680,000 after buying an additional 4,013 shares in the last quarter. Finally, Twinbeech Capital LP boosted its position in Apellis Pharmaceuticals by 47.3% during the fourth quarter. Twinbeech Capital LP now owns 13,152 shares of the company's stock worth $330,000 after purchasing an additional 4,225 shares during the period. 96.29% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Invesco Ltd.在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 23.5%。Invesco Ltd.目前擁有 225,976 股該公司的股票，價值 5,677,000 美元，此前在上個季度又購買了 42,960 股。Mackenzie Financial Corp 在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 25.4%。Mackenzie Financial Corp 目前擁有 96,211 股該公司的股票，價值 2,424,000 美元，此前在上個季度又購買了 19,500 股。NewEdge Advisors LLC 在第四季度購買了 Apellis Pharmaceuticals 的新頭寸，價值 366,000 美元。Virtus Investment Advisers LLC 在第四季度將其在 Apellis Pharmaceuticals 的股份增加了 17.4%。Virtus Investment Advisers LLC 目前擁有 27,086 股該公司的股票，價值 680,000 美元，此前在上個季度又購買了 4,013 股。最後，Twinbeech Capital LP 在第四季度將其在 Apellis Pharmaceuticals 的持倉增加了 47.3%。Twinbeech Capital LP 目前擁有 13,152 股該公司的股票，價值 330,000 美元，此前在此期間又購買了 4,225 股。96.29% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>Several research analysts recently commented on the stock. Bank of America upgraded shares of Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $28.00 target price for the company in a report on Wednesday, January 21st. JPMorgan Chase &amp; Co. restated a &#34;neutral&#34; rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Barclays increased their target price on shares of Apellis Pharmaceuticals from $24.00 to $41.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, April 1st. Raymond James Financial cut shares of Apellis Pharmaceuticals from a &#34;moderate buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, April 1st. Finally, Wells Fargo &amp; Company cut shares of Apellis Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and increased their target price for the stock from $26.00 to $41.00 in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of &#34;Hold&#34; and a consensus price target of $34.89.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票進行了評論。美國銀行將 Apellis Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並在 1 月 21 日的報告中設定了 28.00 美元的目標價。摩根大通在 4 月 1 日的報告中重申了 “中性” 評級，並將 Apellis Pharmaceuticals 的目標價設定為 41.00 美元（上調自 37.00 美元）。巴克萊在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的目標價從 24.00 美元提高至 41.00 美元，並給予該股票 “等權重” 評級。雷蒙德·詹姆斯金融在 4 月 1 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “適度買入” 下調至 “持有”。最後，富國銀行在 4 月 17 日的報告中將 Apellis Pharmaceuticals 的股票評級從 “超配” 下調至 “等權重”，並將該股票的目標價從 26.00 美元提高至 41.00 美元。三位股票研究分析師對該股票給予了買入評級，十八位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，Apellis Pharmaceuticals 目前的平均評級為 “持有”，共識目標價為 34.89 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 APLS 研究報告</strong></p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，以納斯達克代碼：APLS 交易，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。該公司的研發工作集中在調節補體蛋白，以解決一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>該公司的主要上市產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，目前正在對其他視網膜疾病進行持續研究。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Apellis Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Beats Estimates By $0.53 EPS

Market Beat

Apellis Pharma

Beam Therapeutics

景順投資管理

美國銀行

摩根大通

巴克萊銀行

瑞傑金融

富國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Apellis Pharmaceuticals（納斯達克股票代碼：APLS）公佈季度財報，每股收益比預期高出 0.53 美元